MedSource has over twenty years of experience in the CRO industry, with particular experience with rare disease clinical research development. Our expertise as a full service CRO has allowed us the opportunity to execute complex clinical trials across challenging disease states that affect both rare and orphan patient populations. MedSource’s broad industry experience allows us to support our biotech and pharmaceutical customers across all trial phases and study designs, from exploratory to registrational. When partnering with MedSource for a clinical trial, our team will provide the diverse experience, attention, focus, and expertise needed to handle even the most complex and challenging trial within the rare disease patient population.
We’ve participated in more than 700 clinical trials globally, of which more than 100 have been in rare or orphan diseases, covering a broad range of indications and therapeutic areas. The breadth of our therapeutic experience and focus in rare and orphan disease clinical trials includes: Huntington’s Chorea, Fragile X Syndrome, and Status Epilepticus among others.